ILEAL POUCH 4/15: What can we learn from the TaTME Registry on benign disease?

Roel Hompes from the Academic Medical Center of Amsterdam talks about the lessons learned from the international TaTME registry for benign disease. After making a comprehensive review of all the developing phases of TaTME, Dr. Hompes explain how the international registry was designed as well as which were the initial variables that were studied. TaTME cases for benign disease represent less than 10% of all the registered data with high variability of indications. Technical variations when compared to TaTME for cancer, learning curve issues, postoperative outcome are discussed. Some of the current drawbacks and areas for improvement of the TaTME benign disease registry are also reviewed.